Sometimes, success can destroy you.

To see what I mean, consider the rise and fall of Peloton...

Peloton Interactive (PTON) had a pretty good thing going. The company fostered an almost fanatical devotion in its customers – first, they'd spend $2,000 on its exercise bike, then they'd pay more for a subscription to interactive spin classes.

The bike and classes may be expensive, but they're great. At least two members of our research team are fans. I personally ride two times a week and love Peloton's mini-bootcamp classes.

And business was booming... until the pandemic happened. Then things went from booming to bonkers.

Suddenly, Peloton was selling more than a billion dollars' worth of exercise equipment in a single quarter. Everyone was stuck at home, and a Peloton became one of the hot things to own.

But Peloton wasn't ready. So the mistakes started happening.

The company couldn't make its bikes fast enough. Shipments lagged. Customers complained that quality was falling and that repairs took months. And a new treadmill had a safety defect that killed a small child, forcing a costly recall to repair the units and taking the product off the market for several months.

At the same time, management decided to spend hundreds of millions of dollars to ramp up production and logistics. When the pandemic lockdowns eased, the slowdown in sales became an absolute catastrophe. Peloton had thousands of unsold bikes, a weak balance sheet, and an investor base with no confidence in management.

The company ousted its founding CEO, started laying off employees, discounted its bikes, and began looking for someone to buy it out.

It's a far fall for a company that had convinced investors that it would go on to become the biggest name in global fitness...

At one point, Peloton was valued at $48 billion based on about $3 billion in sales.

Stodgy income investors like us love to point out silly valuations like 16 times sales. We trot them out like little trinkets we've collected at the flea market to show the absurdity that markets can reach. But let's really dig into what that valuation implies...

Stocks derive their valuation from their future cash flows – not the present. So what kind of future was Peloton's $48 billion valuation implying?

First, we have to think of what Peloton would've looked like as a mature business, when it had stopped growing so fast and had reached a steady state of maybe 6% growth per year. A business like that would often be valued around 15 times earnings.

Peloton is not and was never profitable... but let's be generous and say it could someday earn a 30% profit margin.

Under these assumptions, for Peloton to grow into its $48 billion peak valuation, it would have to generate $16 billion in annual sales.

There simply aren't enough people willing and able to buy that many bikes and subscriptions... no matter how hot Peloton's brand is. Even amid the pandemic lockdowns, Peloton's sales only reached $4 billion in its 2021 fiscal year – a quarter of that volume.

Investors ignored all that. And it's because Peloton had a narrative. The story was not that Peloton would turn profitable and grow into its $48 billion valuation by selling stationary bicycles. Rather, Peloton would change the way we work out and capture the entire fitness market.

After all, the company didn't just sell bikes – it sold subscriptions to live exercise classes. It was going to expand into other equipment, apparel, and in-person locations. It would create an entirely new category of the fitness industry.

But it turns out Peloton couldn't even figure out its own inventory levels.

Now here's the thing that Peloton shareholders needed to realize years ago... The old narrative is never coming back.

Right now, Peloton is valued at around $2.2 billion. In a year's time, it could be worth $8 billion... or perhaps $1 billion. We don't have a particular outlook and we're not making a specific call here.

One thing is clear: It will never be worth $48 billion again.

First, there's just the math of it... Peloton needs a rise of more than 2,000% to get back to a $48 billion market cap. That's not likely.

But, more important, it's difficult to build mystique around a company that convinces the market it can change the world. And it's a fragile existence. As you can see, a small tear in the story brings the whole thing down.

And once you lose it... you can't get it back. No amount of success in Peloton's turnaround will bring back the glow of its prior glory. Selling more bikes and subscriptions, adding rowing machines to the product suite, or selling treadmills that don't injure people... these factors can help. They can lead to a rise in the stock. But none will turn Peloton back into the financial darling it once was.

Peloton is an extreme example. But it isn't alone. We've seen this same pattern play out before where a once-beloved technology stock takes a 50% or more plunge.

And with the current boom in AI, there are plenty of opportunities to lose your shirt on a stock that only has a good story... without the financials to back it up.

But there's one signal that "is the most reliable way to filter out the potential winners from the losers in the U.S. stock market."

Most investors have no idea it exists. Or if they do know about it, they've been conditioned to ignore it.

Click here for all the details.

What We're Reading (and Watching)...

Here's to our health, wealth, and a great retirement,

Dr. David Eifrig and the Health & Wealth Bulletin Research Team
September 2, 2026

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Back to Top